Head-to-head · WeighScore
Care Bare Rx vs Gala Health
The verdict
Gala Health takes it — 86/100 to 75/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier.
We may earn a commission if you start care through some of these links, at no extra cost to you. Affiliate partners are listed first — a capped 3-point edge in board order only. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Care Bare Rx | Gala Health |
|---|---|---|
| WeighScore | 75/100 | 86/100 |
| Grade | C | B |
| Scorecard rank | #41 | #10 |
| Semaglutide | From $199/mo (shared weight-loss price) | Not disclosed |
| Tirzepatide | From $199/mo (shared weight-loss price) | $179/mo |
| Coverage | Multi-state | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #41 · C
Strengths
- Oral tirzepatide as well as injectable — rare on this board
- Brand Ozempic (from $705/mo) and oral Rybelsus beside the compounded line
- LegitScript certified and HIPAA compliant
- One platform if you also want hair, TRT, sexual health or NAD+
Where it loses points
- The advertised "from $199/mo" is one figure shared across all weight-loss treatments — neither molecule priced separately
- Per-dose pricing is quiz-gated, so a titrated cost cannot be modelled beforehand
- No named clinicians, founding year or parent company disclosed
- Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
Graded #10 · B
Strengths
- Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
- Available in all 50 states
- Keeps a brand-name path open (Ozempic listed at $1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet
- Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 43 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.